Compass Pathways reports 52-week Phase 3 trial results for psilocybin TRD drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. SPY
2. WBD
3. PSKY
4. NVDA
5. TSLA
6. USO
7. AMD
8. COHR
9. META
10. AMC

Go back to Compass Pathways reports 52-week Phase 3 trial results for psilocybin TRD drug
(NASDAQ: CMPS) Delayed: 15.01 -0.18 (1.18%)
Previous Close $15.19    52 Week High $ 
Open $15.50    52 Week Low $ 
Day High $15.55    P/E N/A 
Day Low $14.88    EPS $ 
Volume 3,449,019